CorMedix Q2 2024 Earnings Report

Reported a net loss due to increased operating expenses, driven by higher S&M and G&A expenses related to the DefenCath launch, partially offset by a decrease in research and development expenses.

Key Takeaways

CorMedix reported a net loss of $14.2 million for the second quarter of 2024, driven by increased operating expenses related to the commercial launch of DefenCath. The company is focused on expanding DefenCath's indications and is pleased with the early revenue trajectory from the outpatient launch.

Launched DefenCath in both inpatient and outpatient settings.

Pleased with the early revenue trajectory from outpatient launch.

Making progress on the inpatient P&T formulary process.

Setting the stage for expanded indications for the DefenCath technology.

Previous year: -$0.25

+0.0%

Gross Profit